Home | Welcome to Contract Pharma   
Last Updated Thursday, October 23 2014
Print

Financial Report: Covance



Published May 2, 2014
Covance

1Q Revenues: $666.3 million (+5%)

1Q Earnings: $50.8 million (+6%)

Comments: Late-Stage Development revenues were up 8% to $402 million in the quarter. Central labs and clinical development were up 11% and 6%, respectively, offsetting a decline in market access services. Early Development revenue was up 5% to $218 million, with growth in clinical pharmacology, research products, and nutritional chemistry offsetting the sale of the Seattle genomics lab and declines in toxicology and discovery support. 


blog comments powered by Disqus
Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On